Federal Judge Asks About Overdue Status Report in 340B Dispute Resolution Case

Florence Pan headshot
U.S. District Judge Florence Pan signaled her displeasure with NACHC and the federal government for missing a Sept. 3 deadline for a legal filing.

A federal district judge in Washington, D.C., yesterday ordered community health centers to answer why she should not dismiss their lawsuit against federal health officials over the administrative dispute resolution process for the 340B program.

Judge Florence Pan of U.S.

Read More »

MedPAC May Back a Cut in Part B Drug Payments, This Time Not for 340B Hospitals Only

chart indicating average sale price of drugs MedPAC
MedPAC is considering whether to recommend reducing the 6% add-on to Part B drug reimbursement to decrease the incentives for providers to use higher-priced drugs.

Congressional Medicare advisers are weighing whether to recommend converting the 6% add-on to Part B drug reimbursement to a fixed fee capped at $175 for drugs that cost $15,000 or more, phased in starting with drugs costing above $700.

Medicare

Read More »

News Alert

Becerra Says Legislation Is Needed to Strengthen HHS Authority to Address 340B Contract Pharmacy Pricing Denials

Xavier Becerra speaking to the press
Congress needs to give HHS more more regulatory power and money if its wants the department to do more about drug companies that curtail the use of 340B drugs in contract pharmacies, HHS Secretary Xavier Becerra told House members in a Sept. 1 letter.

U.S. Health and Human Services Secretary Xavier Becerra told members of Congress on Thursday that his department is doing all it can with the tools it has to address drug manufacturers’ denials of 340B pricing involving contract pharmacies.

If lawmakers

Read More »

340B Report Exclusive: CMS May Owe 340B Hospitals More Money Than Anticipated

health care worker inserts IV into patient's arm
There have been various estimates of how much it will cost the U.S. government to remedy unlawful Medicare Part B drug payment cuts for 340B hospitals.

The potential cost to the U.S. government next year of remedying unlawful Medicare Part B drug payment cuts for 340B hospitals could be higher than federal Medicare officials think.

The U.S. Centers for Medicare & Medicaid Services in mid-July put

Read More »

With Just a Month to Go, HRSA Releases First FY 2022 Manufacturer 340B Audit Result

Unichem building mounted sign
Unichem Pharmaceuticals USA must repay 340B covered entities for overcharges found during an FY 2022 340B program compliance audit.

Generic drug manufacturer Unichem Pharmaceuticals USA must repay 340B covered entities for overcharges found during a 340B program compliance audit, the U.S. Health Resources and Services Administration (HRSA) said yesterday.

HRSA has been auditing five drug manufacturers per year for

Read More »

Advocates Urge Feds to Allow Distressed Rural Hospitals to Remain 340B Eligible

Save Our Hospital lawn sign
Financially distressed critical access hospitals should be allowed to keep their 340B drug discounts if they opt under a new federal law to downgrade into emergency hospitals to remain solvent, rural health advocates told CMS in comments on proposed rules to implement the law.

Congress and the White House should let financially distressed critical access hospitals keep their 340B drug discounts if they opt under a new law to downgrade into emergency hospitals to remain solvent, rural health advocates told federal health officials in

Read More »

Key Takeaways from New Medicare Law and 340B Implications

President Biden signs law while legislators watch at the White House
President Biden signed the Inflation Reduction Act into law on Aug. 16.

The landmark prescription drug pricing legislation that President Joe Biden signed this month is a mixed bag for 340B stakeholders, 340B Health Publisher and CEO Ted Slafsky says in his latest column for Omnicell.

Biden signed the Inflation Reduction Act on

Read More »

Exclusive: HRSA Hasn’t Posted a Limited Distribution Plan Notice to 340B Entities in Almost a Year. No One Outside of the Agency Knows Why.

chart depicts limited distribution plan notices by HRSA in years from 2015 to 2022
HRSA has published no drug manufacturer limited distribution plan notices to 340B covered entities since mid-September 2021.

Last September, the U.S. Health Resources and Services Administration (HRSA) published a drug manufacturers’ notice to 340B covered entities that it was limiting distribution of a medicine that alleviates a side effect of HIV/AIDS treatment.

It was the fifth limited

Read More »

Judge Orders HHS to Respond to Ruling Letting Health Center Challenge 340B Patient Definition

Genesis health care pharmacy workers wearing face masks
A federal appeals court gave South Carolina-based Genesis Health Care another chance to challenge the legality of the 340B drug pricing program's patient definition.

A federal district judge on Tuesday gave federal health officials a Sept. 22 deadline to respond to a higher court’s ruling last month that a South Carolina health center has the right to challenge the legality of the government’s 340B

Read More »

House GOP Lawmaker Reintroduces Bill to Collect and Report 340B Hospital Data

Rep. Bruce Westerman (R-AR) headshot
U.S. Rep. Bruce Westerman (R-Ark.) has reintroduced a bill that would create new reporting requirements for 340B disproportionate share (DSH), children’s, and free-standing cancer hospitals and their child sites.

U.S. Rep. Bruce Westerman (R-Ark.) has reintroduced a comprehensive health care bill he sponsored during the last session of Congress that would create new reporting requirements for 340B disproportionate share (DSH), children’s, and free-standing cancer hospitals and their child sites.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report